Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/1681
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLabaki, C.en_US
dc.contributor.authorSchmidt, A. L.en_US
dc.contributor.authorBakouny, Z.en_US
dc.contributor.authorLabban, M.en_US
dc.contributor.authorEl Zarif, T.en_US
dc.contributor.authorChang, S. L.en_US
dc.contributor.authorMcGregor, B. A.en_US
dc.contributor.authorKibel, A. S.en_US
dc.contributor.authorRebbeck, T.en_US
dc.contributor.authorTrinh, Q. D.en_US
dc.contributor.authorChoueiri, T. K.en_US
dc.date.accessioned2022-04-14T02:13:33Z-
dc.date.available2022-04-14T02:13:33Z-
dc.date.issued2022-
dc.identifier.citationDOI: 10.1200/JCO.2022.40.6_suppl.281 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 281-281. Published online February 16, 2022.en_US
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/1681-
dc.descriptionCairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Andrew Lachlan Schmidten_US
dc.description.abstractBackground: The COVID-19 pandemic has been associated with a significant disruption in healthcare services including cancer screening and diagnosis. Delays in cancer screening and treatment may lead to increased mortality. We aimed to analyze changes in screening, diagnosis and surgical treatment of common GU malignancies in relation to the COVID-19 pandemic. Methods: We evaluated screening, novel diagnoses, and surgical management modalities of prostate cancer (PCa), urothelial carcinoma (UC) and renal cell carcinoma (RCC) within Massachusetts General Brigham, the largest healthcare system in the Northeastern United States, over four 3-month time periods during the pandemic (March 2020- March 2021). The percentage change in screening, diagnoses and management modalities during pandemic periods as compared to the immediate pre-pandemic period (December 2019-March 2020) was calculated as (Nperiod – Ncontrol)/Ncontrol. The difference in “predicted” versus “observed” diagnoses in each pandemic period was compared to the average of the four preceding 3-month periods (March 2019-March 2020) to account for seasonal variation. Results: The first pandemic peak (March-June 2020) was associated with a significant decline across screening, diagnosis and treatment, ranging from -15.7 to -64.8%, followed by a progressive recovery, ranging from -5.9 to +25.1% in the latest period (December 2020-March 2021) (Table). Although 725 diagnoses were “missed“ between March and June 2020 as compared to the previous 12 months, 971 diagnoses were “recovered” between June 2020 and March 2021. Conclusions: A substantial disruption in the screening, diagnosis and treatment of GU malignancies was observed early in the pandemic, followed by a progressive rebound and recovery. The highest declines were observed for PSA screening, and the lowest for cystectomy procedures, reflecting triaging of care based on severity during the pandemic.en_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.titleTemporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.en_US
dc.typeArticleen_US
dc.relation.conference2022 ASCO Genitourinary Cancers Symposiumen_US
dc.identifier.doi10.1200/JCO.2022.40.6_suppl.281-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.grantfulltextnone-
Appears in Sites:Cairns & Hinterland HHS Publications
Show simple item record

Page view(s)

54
checked on Jan 3, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.